Opinion: Treasury’s Investment Curbs Need Clear Technology Boundaries
Treasury’s October 22 proposal would add biotechnology to outbound investment rules and update which technology transactions require notification or are prohibited.
Restrictions on U.S. investment tied to adversaries’ military and surveillance capabilities are defensible. Their value depends on defining the covered technologies and transactions precisely enough to address those risks while preserving legitimate investment.
What the release says
Treasury proposed bringing biotechnology into its outbound investment rules on October 22, part of a broader rulemaking that would reshape which technology transactions U.S. investors must report and which they cannot undertake. The announcement opens a comment process; it does not make the proposed changes final.
Treasury says the proposal implements the Comprehensive Outbound Investment Security Act, or COINS Act, enacted as part of the fiscal 2026 defense authorization law. The law builds on the existing Outbound Investment Security Program and directs both notification requirements and prohibitions for specified transactions involving covered foreign persons.
The law identifies five technology sectors: semiconductors and microelectronics, artificial intelligence, quantum information, high-performance computing and supercomputing, and hypersonic systems. Treasury says it used additional authority in the law to include biotechnology in the proposed regulations.
The proposal also addresses U.S. persons’ controlled foreign entities, transaction exceptions, notification information, confidential submissions and requests for nonbinding feedback. Its knowledge standard and expectations for reasonable, diligent inquiry would affect how investors assess a transaction before proceeding.
Read the official release: Treasury Issues Proposed Rule to Implement Comprehensive Outbound Investment National Security ActOur centrist perspective
The distinction between a transaction that requires notification and one that is prohibited is central to the policy’s reach. A sector name alone does not tell an investor which category applies; Treasury’s technical definitions and transaction rules would determine that.
Biotechnology makes that boundary especially consequential. Adding an entire field to the proposal is a starting point for defining coverage, not evidence that every investment in that field presents the same security concern. The relevant test is how the final technical criteria connect covered investments to the capabilities the law addresses.
The tradeoffs
Treasury argues that restricting these investments can prevent foreign adversaries from using U.S. capital to develop threatening technologies. Clear criteria could support that aim and help investors identify permitted activity. Ambiguous thresholds could discourage legitimate transactions or leave difficult cases unresolved. The announcement offers no results showing how the expanded framework would perform.
What to watch next
- Treasury invites comments on transaction scope, definitions, notifications, penalties and enforcement. It directs readers to the official proposed rule for the comment deadline; the release itself does not supply a calendar date.
- Final implementing regulations will set an effective date. The most consequential details will be the technical thresholds, exceptions and inquiry requirements that separate reportable deals, prohibited deals and activity outside the program.
This is an editorial interpretation, not an official agency statement. Factual summaries rely on the linked release; implications and recommendations are our opinion. How we work
